Data / Form D filings / Kestrel Therapeutics Inc.
Kestrel Therapeutics Inc.: Form D filings
Kestrel Therapeutics Inc., a biotechnology company in Boston, MA, filed 4 Form D notices with the SEC between 2021 and 2025. The latest, on August 12, 2025, reports $5 million sold of a $10 million offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- Attn: Pagliuca Harvard Life Lab, 127 Western Ave., Boston, MA, 02134
- Phone
- (617) 460-3772
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1853373
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | New notice | $10,000,000 | $5,000,000 | $5,000,000 | 6 | Jul 28, 2025 | sec.gov |
| Feb 21, 2025 | New notice | $16,000,000 | $8,000,000 | $8,000,000 | 7 | Feb 7, 2025 | sec.gov |
| Jan 11, 2022 | New notice | $40,000,000 | $7,500,000 | $32,500,000 | 6 | Dec 28, 2021 | sec.gov |
| Mar 25, 2021 | New notice | $2,000,000 | $228,000 | $1,772,000 | 4 | Mar 1, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Nicholas G. Saccomano | Director | |
| Denis G. Patrick | Director | |
| Barbara G. Sosnowski | Director | |
| Omar G. Khalil | Director | |
| Andrew G. Phillips | Director | |
| Frank G. Haluska | Executive Officer, Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Aug 11, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Kestrel Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.